ICU blood test may predict deadly clots
NCT ID NCT06357403
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This observational study will follow 1300 critically ill adults in intensive care to see if a blood test called anti-factor Xa activity can predict dangerous blood clots (deep vein thrombosis or pulmonary embolism). Researchers will also track bleeding risks, quality of life, and survival. The goal is to better understand how to prevent clots in very sick patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna
RECRUITINGVienna, 1090, Austria
Contact
-
Department of Internal Medicine, Medical University of Graz
RECRUITINGGraz, Styria, 8063, Austria
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.